Sparfloxacin is a third-generation fluoroquinolone antibiotic. It inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and repair, ultimately leading to bacterial cell death.
The medication is active against various clinically relevant pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus.
Recommended for:
Clinical studies demonstrate sparfloxacin’s effectiveness in community-acquired pneumonia and chronic bronchitis. Its long half-life allows convenient dosing schedules. The drug maintains activity against certain resistant bacterial strains.
Indicated for the treatment of infections caused by microorganisms susceptible to sparfloxacin. Used to eradicate bacterial pathogens, reduce inflammation, and prevent complications. Exhibits bactericidal activity.
Administer orally with sufficient water. Dosage and duration should be determined by a healthcare professional depending on the type and severity of infection. Patients are advised to avoid excessive sunlight exposure during therapy.
Contraindications
Side Effects
